At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
ST266 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Masked, Randomized, Phase 2 Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model
In Brief
A Phase 2 clinical trial evaluating ST266 and Saline (0.9% NaCl) for Allergic Conjunctivitis. Completed, enrolled 70 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionFeb 2017
Study CompletionNov 2017
TodayJul 2026
First PostedNov 30, 2016
Enrollment StartDec 1, 2016
Primary CompletionFeb 1, 2017
Study CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.6 years ago
Interventions
ST266biological
One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
Saline (0.9% NaCl)drug
One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.